The concept of tissue renin-
Introduction
Over the last three decades it has become increasingly clear that bioactive angiotensin peptides can be generated not only in the systemic circulation but also as local hormones in several tissues and organs. Classically, the renin-angiotensin system (RAS) has been considered a hormonal circulating system whose final and bioactive product angiotensin II (Ang II) is produced with participation of two critical enzymes, e.g. renin and the angiotensinconverting enzyme (ACE).
Renin, secreted by the juxtaglomerular cells of the kidney, cleaves circulating angiotensinogen (a tetradecapeptide delivered by hepatocytes), resulting in angiotensin I (Ang I, 10 aminoacids), which is apparently inactive and is further hydrolyzed to the active Ang II (8 aminoacids), by ACE released into the blood by pulmonary tissue. Through vasoconstriction and aldosterone secretion, Ang II plays an important role in the maintenance of blood pressure and electrolyte balance.
Since the identification of the classical enzyme cascade that produces active Ang II in the circulating blood experimental support has accumulated in favour of the presence of reninlike activity within many tissues and organs. 1 Thus the notion of the extrarenal RAS was established, leading to the concept of RAS as a unitary hormonal system, with circulating and tissue components. 2 On the other hand, it has been established that the octapeptide Ang II is not the only active component of the RAS. New peptides were identified as metabolic products of Ang II, with similar or different functional properties. The heptapeptide angiotensin III (2-8) (Ang III) has physio-pharmacological effects similar with Ang II, mediated by their common receptors, the AT 1 and AT 2 types. 3 Different properties were demonstrated for the hexapeptide angiotensin IV (3-8) (Ang IV) and for the heptapeptide (1-7) (Ang 1-7), which are generated by tissue proteases and have specific receptors. 4 During the last decade it has been established that, apart from its classical actions, Ang II exhibits various other effects induced by direct action on its receptors or via local effects of the angiotensin metabolites. Thus, RAS has been proposed to serve as a complex humoral system provided with endocrine, paracrine, autocrine and intracrine properties. 5 Our mini-review will outline current knowledge concerning the enzymatic cascade for the circulating and local biosynthesis of angiotensin peptides, as well as their pleiotropic hormonal actions.
Angiotensin Forming Enzymes and Angiotensinases
The first stage of angiotensin biosynthesis is represented by the circulating prorenin-renin which is derived mainly from the kidney, but also from many other tissues and organs (heart, brain, adrenal cortex, uterus and ovary, prostate, salivary glands, pancreas, etc.). In addition, there is growing evidence indicating ability of various tissues to take up circulatory prorenin and renin, via specific cellular receptors and leading to local angiotensin synthesis ( Figure 1 ). 5 Several reports have indicated the presence of renin receptors and specific mRNA for angiotensinogen in the cardiac muscle and vascular smooth muscle cells, leading to the conclusion that angiotensins could act either before or after internalisation and retention in the target cell. 6 These observations raised the possibility that a complete intracellular RAS can exist in some tissues.
Beside the circulating renin of renal origin, which is an acid aspartate-protease, there are at least two categories of tissue renin-like enzymes (isorenins). 7 The first category is represented by tissue cathepsins (G, D, and E) which are lysosome serine-proteases ensuring a local capacity for the lysis of angiotensinogen to Ang I, as the common precursor of bioactive angiotensins. While cathepsin G is present in human neurotrophils and activates circulating prorenin, cathepsin D was found in the heart and vascular smooth muscle and stimulates myocyte growth. In turn, cathepsin E is involved in the biosynthesis of Ang I and endothelin.
The second category of tissue renin-like enzymes is represented by tonin, which is a cytosolic serine-protease which allows direct synthesis of Ang II from tissue angiotensinogen. 8 Interesting cognitive acquisitions were also obtained for enzymes that convert inactive Ang I to active Ang II. The classic angiotensin-converting enzyme (ACE1) is a zinc metallopeptidase, located predominantly at the luminal surface of pulmonary vascular endothelium, which cleaves the histidylleucine dipeptide from inactive Ang I, producing active Ang II. Being a dipeptidylcarboxypeptidase, ACE1 is rather nonspecific in the way it hydrolyses several different substrates, including bradykinin and opioid peptides.
Ang II has been detected in plasma and tissues even when ACE1 is inhibited, indicating a role for other enzymes in the conversion of Ang I to Ang II. In the human heart, for instance, the major ANG (1-9) (des-leu-Ang 1)
Ang II forming enzyme is chymase. 9 This enzyme belongs to the family of myocardial cathepsins with angiotensin forming activity. Unlike the converting enzyme present mainly in the atria and endothelial cells, chymase has a predominantly ventricular localisation and does not inactivate bradykinin. 10 Recently a new homologous angiotensin conversion enzyme named ACE2 has been discovered in heart, kidney, liver, intestine. 11 This new converting enzyme induces the hydrolysis of the last aminoacid of Ang I producing angiotensin (1) (2) (3) (4) (5) (6) (7) (8) (9) , an inhibitor of classical ACE1 and a precursor for the vasodilating Ang 1-7. Angiotensin (1-9) would thus limit the formation and actions of Ang II, contributing to the autoregulation of the local circulation. 12 In addition, the proteolytic activity of ACE2 is 400 times higher using Ang II as substrate than using Ang I. 13 ACE2 is not inhibited by captopril, lisinopril or enalapril and appears significantly increased (as is bradykinin) in patients with essential hypertension treated with ACE1 inhibitors. 14 ACE2 may act as a tissuespecific negative feed-back regulator of the activated RAS, e.g. by vasodilation mediated by Ang 1-7 and bradykinin. 15 In agreement with this view is the observation of reduced ACE2 levels in several rat models of hypertension. 16 The actions of both ACE1 and its homologue ACE2 seem to be more complex than originally believed. Beside their function as key regulators within RAS, they also hydrolyze some other peptide substrates (des-Arg-bradykinin, neurokinins, apelin, dynorphin A [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] ). The precise interplay between tissue ACE1, ACE2 and their substrates and by-products are still unclear. At first sight, ACE1 seems an unlikely candidate for a signal transduction molecule as it is a zinc metallopeptidase and the cytoplasmic domain of the enzyme is short (only 29 amino acids). However, at least two other ectoenzymes, matrix metalloproteinase-1 (MMP-1) and ADAM12, have recently been associated with a signalling function. 17 On the other hand, ACE1 inhibitors and bradykinin activate several kinases (caseinkinase-2, MAP-kinase, Jun (N)-terminal-kinase) that may regulate protein synthesis by interacting with the nucleus of the cell, as a result of the recently described phenomenon of outside-in signalling. 18 The activated pathway includes CK2, the phosphorylation of ACE Ser1270, the activation of ACE-associated JNK, and the subsequent nuclear accumulation of phosphorylated c-Jun. This signalling pathway ultimately increases ACE1 expression in vitro and in vivo. Recent results show that ACE1 can be added to the list of nonreceptor cell surface proteins that play a role in endothelial cell signalling. The identification of ACE1 as a signalling molecule that can be activated by the binding of ACE1 inhibitors may account for some of the beneficial effects of this class of compounds on the cardiovascular system. By this mechanism intracellular signalling could be an important pharmacological mechanism of the ACE1-inhibitors action.
Angiotensinases are peptidases that generate active or inactive angiotensin peptides, altering the ratio between their bioactive forms. While aminopeptidases A and B successively remove the first and the second amino acid of Ang II, producing Ang III and Ang IV, endopeptidases use as substrate Ang I for neutral endopeptidase (neprilysin) or Ang II for prolyl-endopeptidase, to form Ang 1-7. The tissue carboxypeptidases and proteolytic enzymes (pepsin, trypsin, chymotrypsin, etc.) also contribute to the degradation of bioactive angiotensins to inactive fragments.
Physiological and Pharmacological Properties of Angiotensins
The physiological actions of the bioactive angiotensin peptides depend on their chemical structure and on their specificity for the membrane receptors, the true information transducers at the cellular level. Beside the circulating Ang II of renal origin, there are tissue-generated angiotensins, which have predominantly local actions: intracrine, autocrine, paracrine. 5 Angiotensin II Angiotensin II (1-8) is the first and the most active multifunctional hormone of the RAS. Via its interactions with the specific angiotensin receptors it triggers complex cellular signalling events, which have been extensively studied in various tissues and organs. In the mammalian cells, Ang II binds to two distinct high-affinity plasma membrane receptors, AT 1 and AT 2 ( Figure 2 ). Two subtypes of the AT 1 -receptor (AT 1a and AT 1b ) have been identified in rodents, but not in humans. 19 The AT 1 -receptor mediates most of the physiological actions of Ang II, including the control of cardiovascular functions. In the vasculature, AT 1 -receptors are expressed in the smooth muscle cells, while in the heart they are present in cardiomyocytes and fibroblasts. 20 At these levels, Ang II promotes its effects via angiotensin receptors, which trigger intracellular signalling processes, including cross-talk with pathways activated by other vasoactive agents, and is accompanied by the release of other bioactive factors. In response to Ang II stimulation, AT 1 -receptors interact with various heterotrimeric G proteins inducing the phosphorylation of tyrosine-kinases. 21 The intracellular signalling processes are multiphasic, leading to various biological actions.
The AT 1 -receptor activation leads to increased protein tyrosine phosphorylation and to the activation of mitogen-activatedprotein-kinase (MAPK). These processes are associated with growth factors and cytokines as trophic and inflammatory agents. Thus, in addition to its potent vasoconstrictor actions, Ang II has proliferative and pro-inflammatory properties. 22 One of the earliest detectable events resulting from Ang II stimulation is the AT 1 signalling through phospholipids with the involvement of phospholipases C, D and A 2 . While the stimulation of phospholipase C induces a rapid production of 1,4,5-inositol triphosphate (IP 3 ) and release of diacylglycerol (DAG), phospholipase D hydrolyzes phosphatydylcholine to phosphatidic acid and choline and phospholipase A 2 is responsible for the release of arachidonic acid from the cell membrane phospholipids. 21 The phospholipids-derived second messengers produced by Ang II-activated phospholipases induce multiple subsequent events (release of Ca 2+ from the sarcoplasmic reticulum, activation of protein-kinase C by DAG, generation of eicosanoids, etc). AT 1 -receptors have been cloned and pharmacologically characterised using selective antagonists such as losartan and other diphenylimidazole derivatives.
AT 2 -receptors are normally expressed in foetal and adult tissues including pancreas, heart, kidney, adrenals, ovary, myometrium, brain and vasculature. In the blood vessels, AT 2 -receptors are prevalent in the adventitia and in the media, modulating AT 1 -mediated effects by inducing vasodilation, NO generation and antiproliferative properties. 21 Recent data have demonstrated that AT 2 -receptors may counteract some of the actions of the AT 1 -receptors. Being found in higher amounts in the foetal tissues, AT 2 -receptors have been considered factors that stimulate growth and development. AT 2 -receptors are preferentially expressed by various secretory cells, and are activated by for both circulating and locally generated angiotensins. 23 Such an intrinsic RAS can be found in the case of hepatic Kupffer cells, pancreatic cells, adrenal cortex, prostate, male and female genital tracts, brain and other tissues and organs.
The prevalence of the AT 1 -receptors in various peripheral tissues and organs and in certain central nervous structures is consistent with the involvement of this receptor in most of the classical and newly-discovered actions of Ang II, including its trophic cardiovascular effects. AT 2 -receptors, as already noted, have antagonic properties, being involved in the local blood flow control as a vasodilating mechanism. 24 Although they exhibit a similar binding affinity for Ang II, AT 1 and AT 2 -receptors share only a Angiotensinogen (1-14)
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Ang ( AT 1 -receptors are abundant in a number of adult tissues but are expressed only to a minor extent in embryonic/neonatal tissues. In general terms, AT 2 -receptors are localised in numerous embryonic and neonatal tissues, but their expression declines rapidly after birth and is then restricted to certain organs and brain areas, situation which suggests that this receptor has a role in the development of the nervous system. 27 As regards the various presumptive targets of Ang II via AT 2 , more data have accumulated regarding the CNS, the heart, the vascular smooth muscles and kidney. It is possible that some of the AT 2receptor-mediated brain circuitry may function to counteract the stimulatory actions of Ang II on some of the physiological processes such as vasopressin secretion.
A definite physiological role has not been attributed to the AT 2 -receptor in the heart. It has, however, been reported that an inhibition of cardiac AT 2 -receptors in vivo results in amplification of the immediate left ventricular growth response to Ang II, which is associated with enhanced protein kinase C translocation and reduced left ventricular cGMP content. 28 It has been demonstrated that Ang II exerts opposite effects on the growth of certain cells within blood vessels by binding to either AT 1 or AT 2 -receptors. Whereas Ang II induces cell proliferation by activating its AT 1 -receptor, stimulation of the AT 2 -receptor inhibits cell growth in different cell types. 29 The growthsuppressing effects that are mediated by AT 2receptors do not involve repression of fos and c-jun gene expression, but are mediated through the inhibition of cyclin D1 expression and cyclin D1-associated kinase activity. 30 According to several studies, AT 2 -receptors in the kidney play a role in controlling pressure natriuresis. Furthermore, stimulation of AT 2receptors modulates AT 1 -receptor-mediated vasoconstriction, and altered AT 2 -receptor function may contribute to an exaggerated vasoconstrictor action to Ang II. 24 Another biological phenomenon which seems to be triggered by the stimulation of AT 2 -receptors is apoptosis. Enhanced AT 2 -receptor levels have been observed in both the cortex and the hippocampus after global ischaemia in the rat brain. These increases occurred during the reperfusion period, suggesting that AT 2 -receptors are somehow connected to the molecular events that eventually lead to delayed neuronal cell death. 31 AT 2 -receptors seem to play an important role for tissue repair, not only in the skin but also in the nervous system. Recently, it has been demonstrated that AT 2 -receptor stimulation directly contributes to the process of axonal regeneration in the CNS of adult rats. Co-treatment with the AT 2 -receptor antagonist PD 123177, but not the AT 1 -receptor antagonist losartan, entirely abolished the Ang II-induced axonal regeneration, suggesting receptor-specific neurotrophic actions of Ang II via the AT 2 -receptor. 32 Separated from the antagonic interactions described above, AT 4 -receptors predominate within the cerebral cortex, hippocampus and basal nuclei, contributing to learning and memory. 33 AT 1-7 (Mas) receptors induce vasodilating, diuretic, apoptotic and antiproliferative effects. The specific actions of bioactive angiotensins take place according to the type and reactivity of the receptors. Ang II has classically described effects, upon arterial pressure and hydroelectrolytic balance, many of them mediated via its catecholamine-, aldosterone-and vasopressinreleasing actions. Many experimental studies have demonstrated that this octapeptide also takes part, through AT 1 -receptors, in stimulating the processes of oxidative stress, inflammation, atherogenesis and cardiovascular modelling. 2 In addition to its multiple actions, Ang II also functions as a precursor for its active fragments, represented by Ang III, Ang IV, Ang V and Ang 1-7 ( Figure 2 ). While Ang III has pressor, dipsogenic and vasopressin-releasing effects similar to Ang II, contributing to the regulation of feeding and drinking behaviour, Ang IV is a vasodilator and stimulates the learning and memory accompanied by effects of longterm potentiation. 3 Intracerebroventricular administration of Ang II, Ang IV (3) (4) (5) (6) (7) (8) or Ang V (3-7) 34 facilitates the conditioned reflexes of avoidance and enhances the associative memory in rat through the activation of acetylcholine release and modulation of NMDA receptors. The deficit in Ang IV production, due to the reduced activity of angiotensin-forming enzymes (induced by genetic causes, age, vascular or metabolic risk factors), might contribute to the progressive neuronal degradation in Alzheimer's disease. 35 Since ACE1 participates in the degradation of the neurotoxic ß-amyloid protein from senile plaques, the ACE1 decrease found in the elderly
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is suggestive of involvement of the cerebral RAS in the multifactorial pathogenesis of Alzheimer's disease. As a major player in vascular homeostasis, RAS proteins constitute an interesting source of candidate genes which may be involved in the pathogenesis of dementia. Among these ACE1, a central enzyme of RAS, presents in its sequence a deletion/insertion polymorphism which has been associated with variations of plasma ACE1 levels and with the risk of cognitive impairment and of dementia in several epidemiological studies. Physiopathological hypotheses suggest a possible involvement of the RAS proteins in the occurrence and evolution of Alzheimer's disease. Moreover, although inconsistent, several case-control studies tend to suggest that this ACE1 genetic polymorphism may constitute a genetic susceptibility factor for dementia. 36 The reduction of ACE1 activity results in a deficit of angiotensin which may contribute to the progressive alterations of memory and learning. One should also note that ACE inhibitors may have moderate effects on cognitive decline in dementias and Alzheimer's disease, while some studies suggest that AT 1 antagonists have a clear beneficial effect. 37 Angiotensin IV Angiotensin IV is involved in blood flow regulation, exploratory behaviour, learning and memory, neuronal development. There is support for an inhibitory influence by Ang II via AT 1 , and a facilitory role by Ang IV via AT 4 , on neuronal firing rate, long-term potentiation, associative and spatial learning. 38 This field of research was redefined by the identification of the AT 4 -receptor as the transmembrane insulinregulated aminopeptidase (IRAP), with Ang IV and hemorphin ligands as competitive inhibitors but not substrates of IRAP. 39 Memory-potentiating AT 4 /IRAP ligands may act as follows: (i) potent inhibitors of IRAP favouring the action of endogenous promnestic peptides; (ii) modulators of glucose uptake interfering with GLUT4 traffick; (iii) agonists of IRAP as a receptor, in the sense of inducing signal transduction via its cytosolic domain. 39 Ang IV effects on memory could be related to elevated expression of ryanodine receptors and the subsequent increase in reticular calcium release. 40 The antiepileptogenic effects of Ang IV are partly mediated by an increase of adenosine A 1 -receptor density, 41 besides dopamine-related events: changes in extracellular dopamine levels in the striatum, prevention of D2-receptor decrease, and an area-specific increase in D1-receptors.
In rat basilar artery nanomolar Ang IV induces an indirect constriction mediated by AT 4 -receptors and endogenous endothelin. 42 Chronic elevation of Ang IV in the brain can induce hypertension that can be treated with AT 1 antagonists. 43 Ang II via AT 1 -receptor favours thrombosis, partially mediated by Ang IV. 44 Ang II activates NF-kappaB a major regulator of inflammation, and upregulates some related proinflammatory genes; such effects are also induced by Ang IV via AT 4 -receptors. 45 
Angiotensin (1-7)
Angiotensin (1-7) produces vasodilation, diuresis and antiproliferative reactions through a specific receptor (Mas), unlike Ang II and Ang III, which act mainly via the AT 1 -receptors. The vasodilator effects of Ang 1-7 are more intense in vessels with intact endothelium than in those with the endothelium removed and are accompanied by the release of nitric oxide, kinins and prostaglandins. Through the inhibition of the pressor and proliferative actions of Ang II, Ang 1-7 behaves like a true counteracting factor. In agreement with these data a hypothesis has been proposed, referring to a possible balance between the vasoconstrictor and hypertensive properties of Ang II and the actions of Ang 1-7. 12 Our studies on the vascular effects of Ang 1-7 in isolated rat thoracic aorta ring preconstricted with phenylephrine have shown that, beside the well-known endothelium-dependent relaxation, Ang 1-7 can inhibit the vasoconstriction induced by Ang II. High concentrations (10 -6 -10 -5 M) of Ang 1-7 produced vasoconstriction which was inhibited by the AT 1 -receptor blocker losartan, but was not influenced by PD 123319, a blocker of the AT 2 -receptor. Furthermore, A779, a specific blocker of Ang 1-7, significantly inhibited only the vasodilating response but not the vasoconstricting effects of Ang 1-7. 46 These data confirm that Ang 1-7 is one of the active components of the RAS, involved as a possible counter-regulatory factor for the vasoconstrictor effects of Ang II. They also show that this effect may be limited by the fact that high doses of Ang 1-7 determine vasoconstriction mediated by AT 1receptors. 38 Biphasic modulation of the Ang II vasoconstriction by Ang 1-7 could contribute to the RAS self-regulation and re-establishment of the vascular balance ( Figure 3 ).
Ang 1-7 counteracts the cardiovascular actions of Ang II, and the development of heart failure, also having cardioprotective effects after induction of myocardial infarction (MI). Peripherally Ang 1-7 produces antidiuretic effects, while centrally it increases baroreflex sensitivity and mediates the positive effects of ACE inhibitors on the induced baroreflex in rats. 47 Ang 1-7 interacts with the blood pressure-lowering and cardioprotective peptide bradykinin; 48 and potentiates BK action on the B2-receptor by binding to the active site of ACE1 and by a direct or indirect interaction of its receptor with B2. Recent experiments have identified Mas as a functional receptor for Ang 1-7, expressed in various tissues 47 Ang 1-7 activates the sodium pump, hyperpolarises cardiomyocytes and re-establishes impulse conduction during ischaemia-reperfusion. 50 Ang 1-7 infusion after MI reduces myocyte size and attenuates ventricular dysfunction and remodelling. Ang 1-7 reduces cardiomyocyte growth via Mas. Because Ang 1-7 is elevated after ACE inhibitors or AT 1 blockers, it may contribute to their beneficial effects on cardiac dysfunction and ventricular remodelling after MI, 51 while the increase in ACE2 after MI suggests that it plays an important role in the negative modulation of RAS after cardiac injury. 52 Ang 1-7 blocks Ang II actions on norepinephrine release at the central level, involving nitric oxide, AT 2 and/or Mas receptors and local BK generation. 53 The chronic hypotensive effects of losartan in rats are mediated in part by Ang 1-7. 54 The novel role of ACE2 in hydrolyzing other peptides (apelin, opioids, kinins) reinforces the possibility that peptide systems other than RAS may also participate in regulating cardiovascular and renal function. 55 An ACE2 role in cardiovascular regulation is also supported by its mRNA expression profile in a variety of mouse tissues. 56 Mas and AT 1 form a constitutive hetero-oligomeric complex unaffected by agonists or antagonists of the two receptors, with Mas as antagonist of AT 1 , since mice lacking the Mas gene show enhanced Ang II vasoconstriction. 57 In the kidney ACE2 is present in tubular and glomerular epithelium and in the media and endothelium of interlobular arteries, while in renal disease and in transplanted kidneys neo-expression of ACE2 occurs in glomerular and peritubular capillary endothelium. 58 ACE2mediated production of Ang 1-7 is an important component of the proximal tubular RAS. 59 
Tissue Renin-Angiotensin Systems
Since all the components of the RAS were detected in many tissues and organs, numerous investigations were made concerning their physiological and pathophysiological role.
The multiple intrarenal actions of Ang II are based on its predominantly local synthesis and on the presence of angiotensin AT 1 -receptors within the glomerular vessels and various tubular segments. There is a density gradient of these receptors, demonstrated by their much higher amounts in the superficial glomeruli than in the juxtamedullar ones. Autoradiographic studies with tritiated Ang II have demonstrated that the angiotensin receptors can be found mostly in the basal membrane of the tubular epithelium and of the mesangial cells. This distribution provides the contractile effect of the peptide on mesangial cells and the control of Na + and water proximal At the level of the renal medulla the angiotensin receptors are disposed as longitudinal stripes corresponding to the vasa recta from the internal region of the external medulla. As regards the interrelations between the intrarenal distribution of the angiotensin receptors and those of other biologically active peptides (endothelin, natriuretic peptides, ADH, etc.) it has been observed that they have similar densities, higher in the glomeruli and lower in the medullar area. On the functional level, Ang II contributes, by its pre-and post-glomerular vasoconstricting effects, to the control of the glomerular filtration rate. 60 At the same time, the vasa recta and the peritubullary capillaries, being the most sensitive to the vasoconstricting action of Ang II, contribute both to the tubulo-glomerular feedback and to the control of the water and ions elimination. Through such volume regulatory mechanisms, achieved by the process of pressure-diuresisnatriuresis the increase in the peripheral basal vascular tone, Ang II participates in the long-term regulation of arterial blood pressure.
Previous reports have shown that the liver is involved not only in the biosynthesis of the circulating angiotensinogen, but as well in the genesis and actions of the various components of the local RAS. Some experimental data suggest that Ang II exerts its vasoconstrictive actions on the postsinusoidal venules, through the AT 1receptors, participating in the pathogenesis of portal hypertension and liver cirrhosis. In addition, AT 1 -receptors activate the Kupffer cells which release cytokines involved in the proliferation of stellate cells and in the fibrotic processes that take place in the liver. 61 In the endocrine pancreas Ang II induces a dose-dependent reduction of glucose-stimulated insulin release, mediated by AT 1 -receptors located on the surface of the islet beta cells. 23 In the exocrine pancreas, AT 1 and AT 2 -receptors have been identified in the acinar cells, pancreatic ducts and vasculature. An up-regulation of the RAS components by pancreatitis might increase oxidative stress, leading to hypoxia and pancreatic injury. In pathological circumstances Ang II contributes to pancreatic dysfunction through oxidative damage induced by NADPHdriven generation of reactive oxygen species via AT 1 -receptors. 62 Other enzymatic sources capable of generating reactive oxygen species are xanthine oxidase and nitric oxide synthase which is responsible for the production of NO by the pancreatic vessels elicited by activation of angiotensin receptors.
The locally synthesised Ang II is also involved in the stimulation of steroid hormone biosynthesis in both ovaries and testes. In the ovary, it may allow the development of predominant follicular oestrogen synthesis, followed by an increase in the rate of progesterone-induced ovum maturation. 63 Ang II stimulates angiogenesis, contributing to the intense vascularisation of the corpus luteum. In the normal pregnancy there is a progressive increase of Ang II and aldosterone secretion that predisposes to sodium retention and hypervolaemia.
RAS components have been found in the testes, vas deferens, epididimys and sperm. 64 Ang II inhibits the function of both of Sertoli and Leydig cells by reducing basal and final spermatogenesis induced by FSH as well as testosterone production stimulated by LH. These data suggest that locally synthesised Ang II could negatively modulate the LH stimulation of Leydig cells. All RAS compounds were identified in the human prostate, where Ang II-stimulated norepinephrine release from the prostatic sympathetic nerve endings mediated by AT 1 -receptors intervenes in benign prostatic hyperplasia. 65 The presence of AT 4 -receptors in the prostate suggests the involvement of other angiotensin peptides besides Ang II.
Numerous studies have demonstrated the existence of RAS in both the corticoadrenal and medulloadrenal territories. The adrenal cortex contains more than 70% from the locallysynthesised Ang I and II in the glomerulosa, which is secreting aldosterone. While a sodiumpoor diet increases the amounts of adrenal renin, a sodium-rich intake decreases it, with the corresponding effects on the steroidogenesis and aldosterone secretion. Binding sites for Ang II were identified in the external zona glomerulosa of the adrenal gland. In agreement with these data, AT 1 antagonists inhibit aldosterone secretion induced by K + and ACTH. Unlike ACTH, K + and PGE 1 , which favour the stimulating properties of both adrenal and circulating Ang II, dopamine and pre-adrenomedullin peptide (PAMP) act in an inhibitory direction. Adrenomedullin has vasodilating properties and acts as an adrenal modulating hormone, with diuretic and natriuretic effects induced by blocking the aldosteronereleasing effect of Ang II, accompanied by the inhibition of catecholamine secretion by the medulloadrenal gland. At the medulloadrenal level, Ang II has a function both as a circulating hormonal system and of a local hormone, stimulating the secretion of catecholamines and modulatory peptides (NPY, adrenomedullin, enkephalins).
To the peripheral components of RAS contribute also the central neuroendocrine mechanisms, represented by the stimulation by Ang II of the hypothalamo-pituitary complex, that secretes ADH and ACTH, and also of the periependimary subfornical organ, which is involved in dipsogenesis and regulation of the water intake. 66 The RAS in Cardiovascular Remodelling Finally, we briefly present the main data concerning the involvement of RAS in normal and pathological cardiovascular modelling and remodelling. Both physiological adaptive remodelling during exercise, pregnancy, obesity or aging and the pathological processes, induced by heart disease, arterial hypertension of various causes or endocrine diseases, are based on complex molecular and functional processes in which RAS has a substantial contribution, together with other neuro-humoral factors (catecholamines, ANF, endothelins, reactive oxygen species, etc.).
Stretch of the myocardial fibres activates both the enzymatic cascade which forms Ang II and the genetic expression of AT 1 -receptors. Through these, both locally-synthesised and circulating angiotensins induce changes in myocardial volume, compliance and contractility, mediated by growth factors acting upon myocytes and fibroblasts to induce proliferation, hypertrophy and hyperplasia. Through the AT 1 -receptors, Ang II induces the activation of the G protein coupled with PLC, which leads to fast muscle contraction through increased intracellular calcium, with the involvement also of PKC, tyrosine-kinase, MAPK and free radicals. 67 This leads to the multiphasic contractile and trophic effects of Ang II on the myocardial and smooth muscle cells involved in the cardiovascular remodelling. Angiotensinogen, ACE and Ang II are significantly increased in the myocardium of animals with mechanical distension and heart overwork induced by a stenosis of the thoracic aorta.
In humans, both the increase of preload, induced by some valvular diseases, and of the increased afterload due to arterial hypertension or MI induce in a first phase the activation of the RAS and the secretion of catecholamines producing coronary vasoconstriction and left ventricular hypertrophy. In turn, systolo-diastolic dysfunction produces hypertrophy of the vascular media and the remodelling of conduction vessels by systemic neurohormonal activation. 68 Many clinical trials have demonstrated the beneficial anti-proliferative cardiac and vascular effects induced by ACE inhibitors and AT 1 blockers in the treatment of high blood pressure and heart failure. New perspectives in the treatment of arterial hypertension and heart remodelling are opened by the specific inhibitors of the proteolytic properties of renin (enalkiren, remikiren) and by endopeptidase blockers. In both pathological situations the AT 1 -receptor blockers induce the regression of cardiac hypertrophy and of the contractile and arrhythmic consequences. 68 The briefly presented data in this review, concerning the distribution and multiple functions of RAS justify, we hope, the necessity of rethinking of the physiological and pathophysiological role of this circulating and tissue hormone system. At the same time, 
